Melodiol Global Health Valuation

Is ME1DA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ME1DA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ME1DA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ME1DA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ME1DA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ME1DA. This is calculated by dividing ME1DA's market cap by their current preferred multiple.
What is ME1DA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$3.42m

ME1DA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	-0.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ME1DA's PS Ratio compare to its peers?

The above table shows the PS ratio for ME1DA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
AGH Althea Group Holdings	0.3x	n/a	AU$7.8m
CAN Cann Group	0.8x	n/a	AU$17.3m
CGB Cann Global	9.7x	n/a	AU$5.4m
RNO Rhinomed	1.4x	n/a	AU$11.5m
ME1DA Melodiol Global Health	0.3x	n/a	AU$3.4m

Price-To-Sales vs Peers: Insufficient data to calculate ME1DA's Price-To-Sales Ratio vs. peers for valuation analysis.

Price to Earnings Ratio vs Industry

How does ME1DA's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	38.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	38.5%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: ME1DA is good value based on its Price-To-Sales Ratio (0.3x) compared to the Australian Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is ME1DA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ME1DA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ME1DA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.